KRAS and neoplasm: Upon binding, K-Ras4A blocks the allosteric inhibition of HK1 resulting in an enhanced glucose consumption, which might contribute to the metabolic reprogramming of tumor cells aimed to sustain rapid tumor growth (Amendola et al., 2019).